These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
488 related articles for article (PubMed ID: 33716638)
41. Inhibition of Rho-kinase by Fasudil protects dopamine neurons and attenuates inflammatory response in an intranasal lipopolysaccharide-mediated Parkinson's model. He Q; Li YH; Guo SS; Wang Y; Lin W; Zhang Q; Wang J; Ma CG; Xiao BG Eur J Neurosci; 2016 Jan; 43(1):41-52. PubMed ID: 26565388 [TBL] [Abstract][Full Text] [Related]
54. Commentary: Progressive inflammation as a contributing factor to early development of Parkinson's disease. Pradhan S; Andreasson K Exp Neurol; 2013 Mar; 241():148-55. PubMed ID: 23261765 [TBL] [Abstract][Full Text] [Related]
55. Antagonistic pleiotropic effects of nitric oxide in the pathophysiology of Parkinson's disease. Tripathy D; Chakraborty J; Mohanakumar KP Free Radic Res; 2015; 49(9):1129-39. PubMed ID: 25968946 [TBL] [Abstract][Full Text] [Related]
56. Caffeic acid reduces A53T α-synuclein by activating JNK/Bcl-2-mediated autophagy in vitro and improves behaviour and protects dopaminergic neurons in a mouse model of Parkinson's disease. Zhang Y; Wu Q; Zhang L; Wang Q; Yang Z; Liu J; Feng L Pharmacol Res; 2019 Dec; 150():104538. PubMed ID: 31707034 [TBL] [Abstract][Full Text] [Related]
57. CD73-derived adenosine controls inflammation and neurodegeneration by modulating dopamine signalling. Meng F; Guo Z; Hu Y; Mai W; Zhang Z; Zhang B; Ge Q; Lou H; Guo F; Chen J; Duan S; Gao Z Brain; 2019 Mar; 142(3):700-718. PubMed ID: 30689733 [TBL] [Abstract][Full Text] [Related]
58. The gut microbiome in Parkinson's disease: A culprit or a bystander? Keshavarzian A; Engen P; Bonvegna S; Cilia R Prog Brain Res; 2020; 252():357-450. PubMed ID: 32247371 [TBL] [Abstract][Full Text] [Related]
59. Cx3cr1-deficiency exacerbates alpha-synuclein-A53T induced neuroinflammation and neurodegeneration in a mouse model of Parkinson's disease. Castro-Sánchez S; García-Yagüe ÁJ; López-Royo T; Casarejos M; Lanciego JL; Lastres-Becker I Glia; 2018 Aug; 66(8):1752-1762. PubMed ID: 29624735 [TBL] [Abstract][Full Text] [Related]
60. Post-treatment with an ultra-low dose of NADPH oxidase inhibitor diphenyleneiodonium attenuates disease progression in multiple Parkinson's disease models. Wang Q; Qian L; Chen SH; Chu CH; Wilson B; Oyarzabal E; Ali S; Robinson B; Rao D; Hong JS Brain; 2015 May; 138(Pt 5):1247-62. PubMed ID: 25716193 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]